{"nctId":"NCT02819635","briefTitle":"A Study to Evaluate the Safety and Efficacy of Upadacitinib (ABT-494) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis (UC)","startDateStruct":{"date":"2016-09-26","type":"ACTUAL"},"conditions":["Ulcerative Colitis (UC)"],"count":1302,"armGroups":[{"label":"SS1: Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]},{"label":"SS1: Upadacitinib 7.5 mg","type":"EXPERIMENTAL","interventionNames":["Drug: Upadacitinib"]},{"label":"SS1: Upadacitinib 15 mg","type":"EXPERIMENTAL","interventionNames":["Drug: Upadacitinib"]},{"label":"SS1: Upadacitinib 30 mg","type":"EXPERIMENTAL","interventionNames":["Drug: Upadacitinib"]},{"label":"SS1: Upadacitinib 45 mg","type":"EXPERIMENTAL","interventionNames":["Drug: Upadacitinib"]},{"label":"SS2: Placebo/Upadacitinib 45 mg","type":"EXPERIMENTAL","interventionNames":["Drug: Placebo","Drug: Upadacitinib"]},{"label":"SS2: Upadacitinib 45 mg/Upadacitinib 45 mg","type":"EXPERIMENTAL","interventionNames":["Drug: Upadacitinib"]},{"label":"SS3: M14-675 clinical responders","type":"EXPERIMENTAL","interventionNames":["Drug: Placebo","Drug: Upadacitinib"]}],"interventions":[{"name":"Placebo","otherNames":[]},{"name":"Upadacitinib","otherNames":["ABT-494","RINVOQ"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\nNote: Adolescent participants who are 16 or 17 years old will be eligible to participate if approved by the country or regulatory/health authority. If approval has not been granted, only participants ≥18 years old will be enrolled. Adolescents must weigh ≥ 40 kilograms and meet the definition of Tanner Stage 5 at Screening Visit.\n\n* Diagnosis of ulcerative colitis for 90 days or greater prior to Baseline, confirmed by colonoscopy during the Screening Period, with exclusion of current infection, colonic dysplasia and/or malignancy. Appropriate documentation of biopsy results consistent with the diagnosis of UC, in the assessment of the Investigator, must be available.\n* Active ulcerative colitis with an Adapted Mayo score of 5 to 9 points and endoscopic sub score of 2 to 3 (confirmed by central reader).\n* Demonstrated an inadequate response to, loss of response to, or intolerance to at least one of the following treatments including: oral aminosalicylates, corticosteroids, immunosuppressants, and/or biologic therapies in the opinion of the investigator.\n\nNote: Participants who have had inadequate response, loss of response to conventional therapy, but have not failed biologic therapy (Non-bio-IR) and have received a prior biologic for up to 1 year may be enrolled, however they must have discontinued the biologic for reasons other than inadequate response or intolerance (e.g., change of insurance, well controlled disease) and must meet criteria for inadequate response, loss of response or intolerance to aminosalicylates, corticosteroids, and/or immunosuppressants as defined above.\n\n* If female, participant must meet the criteria for Contraception Recommendations\n* Female participants of childbearing potential must have a negative serum pregnancy test at the Screening Visit and a negative urine pregnancy test at the Baseline Visit prior to study drug dosing.\n\nExclusion Criteria:\n\n* Participant with current diagnosis of Crohn's disease (CD) or diagnosis of indeterminate colitis (IC)\n* Current diagnosis of fulminant colitis and/or toxic megacolon\n* Participant with disease limited to the rectum (ulcerative proctitis) during the screening endoscopy\n* Received cyclosporine, tacrolimus, mycophenolate mofetil, or thalidomide within 30 days prior to Baseline\n* Participant on azathioprine or 6-mercaptopurine within 10 days of Baseline\n* Received intravenous corticosteroids within 14 days prior to Screening or during the Screening Period.\n* Participant with previous exposure to Janus Activated Kinase (JAK) inhibitor (e.g., tofacitinib, baricitinib, filgotinib, upadacitinib).\n* Screening laboratory and other analyses show any abnormal results meeting the exclusion criteria","healthyVolunteers":false,"sex":"ALL","minimumAge":"16 Years","maximumAge":"75 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Substudy 1: Percentage Of Participants Who Achieved Clinical Remission Per Adapted Mayo Score at Week 8","description":"The Adapted Mayo Score is a composite score of UC disease activity based on the following 3 subscores:\n\n1. Stool frequency subscore (SFS), scored from 0 (normal number of stools) to 3 (5 or more stools more than normal)\n2. Rectal bleeding subscore (RBS), scored from 0 (no blood seen) to 3 (blood alone passed)\n3. Endoscopic subscore, scored from 0 (normal or inactive disease) to 3 (severe disease, spontaneous bleeding, ulceration)\n\nThe overall Adapted Mayo score ranges from 0 to 9 where higher scores represent more severe disease.\n\nFor Substudy 1, clinical remission is defined as SFS ≤ 1, RBS of 0, and endoscopic subscore ≤ 1.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"8.5","spread":null},{"groupId":"OG002","value":"14.3","spread":null},{"groupId":"OG003","value":"13.5","spread":null},{"groupId":"OG004","value":"21.4","spread":null}]}]}]},{"type":"PRIMARY","title":"Substudy 2: Percentage Of Participants Who Achieved Clinical Remission Per Adapted Mayo Score at Week 8","description":"The Adapted Mayo Score is a composite score of UC disease activity based on the following 3 subscores:\n\n1. Stool frequency subscore (SFS), scored from 0 (normal number of stools) to 3 (5 or more stools more than normal)\n2. Rectal bleeding subscore (RBS), scored from 0 (no blood seen) to 3 (blood alone passed)\n3. Endoscopic subscore, scored from 0 (normal or inactive disease) to 3 (severe disease, spontaneous bleeding, ulceration)\n\nThe overall Adapted Mayo score ranges from 0 to 9 where higher scores represent more severe disease.\n\nFor Substudy 2, clinical remission is defined as SFS ≤ 1 and not greater than Baseline, RBS of 0, and endoscopic subscore ≤ 1. In Substudy 2, evidence of friability during endoscopy in participants with otherwise \"mild\" endoscopic activity conferred an endoscopic subscore of 2.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.8","spread":null},{"groupId":"OG001","value":"26.1","spread":null}]}]}]},{"type":"PRIMARY","title":"Substudy 3: Percentage Of Participants Who Achieved Clinical Remission Per Adapted Mayo Score at Week 52","description":"The Adapted Mayo Score is a composite score of UC disease activity based on the following 3 subscores:\n\n1. Stool frequency subscore (SFS), scored from 0 (normal number of stools) to 3 (5 or more stools more than normal).\n2. Rectal bleeding subscore (RBS), scored from 0 (no blood seen) to 3 (blood alone passed).\n3. Endoscopic subscore, scored from 0 (normal or inactive disease) to 3 (severe disease, spontaneous bleeding, ulceration).\n\nThe overall Adapted Mayo score ranges from 0 to 9 where higher scores represent more severe disease.\n\nFor Substudy 3, clinical remission is defined as SFS ≤ 1 and not greater than Baseline, RBS of 0, and endoscopic subscore ≤ 1. In addition, evidence of friability during endoscopy in participants with otherwise \"mild\" endoscopic activity conferred an endoscopic subscore of 2.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12.1","spread":null},{"groupId":"OG001","value":"42.3","spread":null},{"groupId":"OG002","value":"51.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Substudy 1: Percentage Of Participants With Endoscopic Improvement at Week 8","description":"Endoscopic improvement is defined as an endoscopic subscore of 0 or 1. Endoscopies were assessed by a blinded central reader and scored according to the following scale: 0 = Normal or inactive disease; 1 = Mild disease (erythema, decreased vascular pattern); 2 = Moderate disease (marked erythema, lack of vascular pattern, any friability, erosions); 3 = Severe disease (spontaneous bleeding, ulceration).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.2","spread":null},{"groupId":"OG001","value":"14.9","spread":null},{"groupId":"OG002","value":"30.6","spread":null},{"groupId":"OG003","value":"26.9","spread":null},{"groupId":"OG004","value":"35.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Substudy 1: Percentage Of Participants Achieving Clinical Remission Per Full Mayo Score at Week 8","description":"The Mayo score is a tool designed to measure disease activity for ulcerative colitis. The Full Mayo score (FMS) ranges from 0 (normal or inactive disease) to 12 (severe disease) and is calculated as the sum of 4 subscores (stool frequency, rectal bleeding, endoscopy \\[confirmed by a central reader\\], and physician's global assessment), each of which ranges from 0 (normal) to 3 (severe disease). Negative changes indicate improvement. Clinical remission per FMS is defined as Mayo Score ≤ 2 and no individual subscore \\> 1.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"10.6","spread":null},{"groupId":"OG002","value":"10.2","spread":null},{"groupId":"OG003","value":"11.5","spread":null},{"groupId":"OG004","value":"19.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Substudy 1: Percentage Of Participants Achieving Clinical Response Per Adapted Mayo Score at Week 8","description":"The Adapted Mayo Score is a composite score of UC disease activity based on the following 3 subscores:\n\n1. Stool frequency subscore (SFS), scored from 0 (normal number of stools) to 3 (5 or more stools more than normal).\n2. Rectal bleeding subscore (RBS), scored from 0 (no blood seen) to 3 (blood alone passed).\n3. Endoscopic subscore, scored from 0 (normal or inactive disease) to 3 (severe disease, spontaneous bleeding, ulceration).\n\nThe overall Adapted Mayo score ranges from 0 to 9 where higher scores represent more severe disease. Clinical response is defined as a decrease from baseline in the Adapted Mayo score ≥ 2 points and ≥ 30% from baseline, and a decrease in RBS ≥ 1 or an absolute RBS ≤ 1).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13.0","spread":null},{"groupId":"OG001","value":"29.8","spread":null},{"groupId":"OG002","value":"49.0","spread":null},{"groupId":"OG003","value":"46.2","spread":null},{"groupId":"OG004","value":"55.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Substudy 1: Percentage Of Participants Achieving Clinical Response Per Partial Mayo Score at Week 2","description":"The Partial Mayo Score is a composite score of UC disease activity based on the following 2 subscores:\n\n1. Stool frequency subscore (SFS), scored from 0 (normal number of stools) to 3 (5 or more stools more than normal).\n2. Rectal bleeding subscore (RBS), scored from 0 (no blood seen) to 3 (blood alone passed).\n\nThe overall Partial Mayo score ranges from 0 to 6 with higher scores representing more severe disease.\n\nClinical response per Partial Mayo Score is defined as a decrease in Partial Adapted Mayo score ≥ 2 points and ≥ 30% from Baseline, plus a decrease in RBS ≥ 1 or an absolute RBS ≤ 1.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"17.4","spread":null},{"groupId":"OG001","value":"23.4","spread":null},{"groupId":"OG002","value":"34.7","spread":null},{"groupId":"OG003","value":"36.5","spread":null},{"groupId":"OG004","value":"55.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Substudy 1: Change in Full Mayo Score From Baseline to Week 8","description":"The Mayo score is a tool designed to measure disease activity for ulcerative colitis. The Full Mayo score (FMS) ranges from 0 (normal or inactive disease) to 12 (severe disease) and is calculated as the sum of 4 subscores (stool frequency, rectal bleeding, endoscopy \\[confirmed by a central reader\\], and physician's global assessment), each of which ranges from 0 (normal) to 3 (severe disease). Negative changes indicate improvement. Clinical remission per FMS is defined as Mayo Score ≤ 2 and no individual subscore \\> 1.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.741","spread":"2.3302"},{"groupId":"OG001","value":"-2.870","spread":"2.9685"},{"groupId":"OG002","value":"-3.589","spread":"2.4984"},{"groupId":"OG003","value":"-4.211","spread":"3.0886"},{"groupId":"OG004","value":"-4.606","spread":"2.8976"}]}]}]},{"type":"SECONDARY","title":"Substudy 1: Percentage Of Participants With Endoscopic Remission at Week 8","description":"Endoscopic remission is defined as an endoscopic subscore of 0. Endoscopies were assessed by a blinded central reader and scored according to the following scale: 0 = Normal or inactive disease; 1 = Mild disease (erythema, decreased vascular pattern); 2 = Moderate disease (marked erythema, lack of vascular pattern, any friability, erosions); 3 = Severe disease (spontaneous bleeding, ulceration).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"6.4","spread":null},{"groupId":"OG002","value":"4.1","spread":null},{"groupId":"OG003","value":"9.6","spread":null},{"groupId":"OG004","value":"17.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Substudy 1: Percentage Of Participants Who Achieved Histologic Improvement at Week 8","description":"The Geboes histologic index includes seven histological features (architectural change, chronic inflammatory infiltrate, lamina propria neutrophils and eosinophils, neutrophils in epithelium, crypt destruction and erosion or ulcers). The Geboes score has 6 grades, each with 3-5 subgrades: Grade 0, structural change only; Grade 1, chronic inflammation; Grade 2, lamina propria neutrophils and eosinophils; Grade 3, neutrophils in epithelium; Grade 4, crypt destruction; and Grade 5, erosions or ulceration.\n\nHistologic improvement was defined as decrease from baseline in Geboes score.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.5","spread":null},{"groupId":"OG001","value":"31.9","spread":null},{"groupId":"OG002","value":"51.0","spread":null},{"groupId":"OG003","value":"44.2","spread":null},{"groupId":"OG004","value":"48.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Substudy 2: Percentage Of Participants With Endoscopic Improvement at Week 8","description":"Endoscopic improvement is defined as an endoscopic subscore of 0 or 1. Endoscopies were assessed by a blinded central reader and scored according to the following scale: 0 = Normal or inactive disease; 1 = Mild disease (erythema, decreased vascular pattern); 2 = Moderate disease (marked erythema, lack of vascular pattern, any friability, erosions); 3 = Severe disease (spontaneous bleeding, ulceration).","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.4","spread":null},{"groupId":"OG001","value":"36.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Substudy 2: Percentage Of Participants With Endoscopic Remission at Week 8","description":"Endoscopic remission is defined as an endoscopic subscore of 0. Endoscopies were assessed by a blinded central reader and scored according to the following scale: 0 = Normal or inactive disease; 1 = Mild disease (erythema, decreased vascular pattern); 2 = Moderate disease (marked erythema, lack of vascular pattern, any friability, erosions); 3 = Severe disease (spontaneous bleeding, ulceration).","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.3","spread":null},{"groupId":"OG001","value":"13.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Substudy 2: Percentage Of Participants Achieving Clinical Response Per Adapted Mayo Score at Week 8","description":"The Adapted Mayo Score is a composite score of UC disease activity based on the following 3 subscores:\n\n1. Stool frequency subscore (SFS), scored from 0 (normal number of stools) to 3 (5 or more stools more than normal).\n2. Rectal bleeding subscore (RBS), scored from 0 (no blood seen) to 3 (blood alone passed).\n3. Endoscopic subscore, scored from 0 (normal or inactive disease) to 3 (severe disease, spontaneous bleeding, ulceration).\n\nThe overall Adapted Mayo score ranges from 0 to 9 where higher scores represent more severe disease. Clinical response is defined as a decrease from baseline in the Adapted Mayo score ≥ 2 points and ≥ 30% from baseline, and a decrease in RBS ≥ 1 or an absolute RBS ≤ 1).","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"27.3","spread":null},{"groupId":"OG001","value":"72.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Substudy 2: Percentage Of Participants Achieving Clinical Response Per Partial Mayo Score at Week 2","description":"The Partial Mayo Score is a composite score of UC disease activity based on the following 2 subscores:\n\n1. Stool frequency subscore (SFS), scored from 0 (normal number of stools) to 3 (5 or more stools more than normal).\n2. Rectal bleeding subscore (RBS), scored from 0 (no blood seen) to 3 (blood alone passed).\n\nThe overall Partial Mayo score ranges from 0 to 6 with higher scores representing more severe disease.\n\nClinical response per Partial Mayo Score is defined as a decrease from Baseline ≥ 1 point and ≥ 30% from Baseline, plus a decrease in RBS ≥ 1 or an absolute RBS ≤ 1.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"27.3","spread":null},{"groupId":"OG001","value":"60.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Substudy 2: Percentage Of Participants Who Achieved Histologic-Endoscopic Mucosal Improvement at Week 8","description":"Histologic-endoscopic mucosal improvement is defined as an endoscopic subscore of 0 or 1 and a Geboes score ≤ 3.1.\n\nThe endoscopic subscore ranges from 0 (normal or inactive disease) to 3 (severe disease with spontaneous bleeding, ulceration).\n\nThe Geboes histologic index includes seven histological features (architectural change, chronic inflammatory infiltrate, lamina propria neutrophils and eosinophils, neutrophils in epithelium, crypt destruction and erosion or ulcers). The Geboes score has 6 grades, each with 3-5 subgrades: Grade 0, structural change only; Grade 1, chronic inflammation; Grade 2, lamina propria neutrophils and eosinophils; Grade 3, neutrophils in epithelium; Grade 4, crypt destruction; and Grade 5, erosions or ulceration.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.6","spread":null},{"groupId":"OG001","value":"30.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Substudy 2: Percentage Of Participants Who Report No Bowel Urgency at Week 8","description":"Bowel urgency was assessed by participants in a subject diary completed once a day.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"21.4","spread":null},{"groupId":"OG001","value":"48.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Substudy 2: Percentage Of Participants Who Reported No Abdominal Pain at Week 8","description":"Abdominal pain was assessed by participants in a subject diary completed once a day.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"23.4","spread":null},{"groupId":"OG001","value":"46.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Substudy 2: Percentage Of Participants Who Achieved Histologic Improvement at Week 8","description":"The Geboes histologic index includes seven histological features (architectural change, chronic inflammatory infiltrate, lamina propria neutrophils and eosinophils, neutrophils in epithelium, crypt destruction and erosion or ulcers). The Geboes score has 6 grades, each with 3-5 subgrades: Grade 0, structural change only; Grade 1, chronic inflammation; Grade 2, lamina propria neutrophils and eosinophils; Grade 3, neutrophils in epithelium; Grade 4, crypt destruction; and Grade 5, erosions or ulceration. Histologic improvement was defined as decrease from baseline in Geboes score.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"22.5","spread":null},{"groupId":"OG001","value":"55.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Substudy 2: Change From Baseline in Inflammatory Bowel Disease Questionnaire (IBDQ) Total Score at Week 8","description":"The Inflammatory Bowel Disease Questionnaire (IBDQ) is used to assess health-related quality of life (HRQoL) in patients with ulcerative colitis. It consists of 32 questions evaluating bowel and systemic symptoms, as well as emotional and social functions. Each question is answered on a scale from 1 (worst) to 7 (best). The total score ranges from 32 to 224 with higher scores indicating better health-related quality of life. A positive change from Baseline indicates improvement.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"21.7","spread":null},{"groupId":"OG001","value":"55.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Substudy 2: Percentage Of Participants With Mucosal Healing at Week 8","description":"Mucosal healing is defined as an endoscopic score of 0 and Geboes score \\< 2.0. The endoscopic subscore ranges from 0 (normal or inactive disease) to 3 (severe disease with spontaneous bleeding, ulceration).\n\nThe Geboes histologic index includes seven histological features (architectural change, chronic inflammatory infiltrate, lamina propria neutrophils and eosinophils, neutrophils in epithelium, crypt destruction and erosion or ulcers). The Geboes score has 6 grades, each with 3-5 subgrades: Grade 0, structural change only; Grade 1, chronic inflammation; Grade 2, lamina propria neutrophils and eosinophils; Grade 3, neutrophils in epithelium; Grade 4, crypt destruction; and Grade 5, erosions or ulceration.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.3","spread":null},{"groupId":"OG001","value":"10.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Substudy 2: Change From Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Score at Week 8","description":"The FACIT fatigue questionnaire was developed to assess fatigue associated with anemia. It consists of 13 fatigue-related questions. Each question is answered on a 5-point Likert scale: 0 (not at all); 1 (a little bit); 2 (somewhat); 3 (quite a bit); and 4 (very much). The total score ranges from 0 to 52, where higher scores represent less fatigue, and a positive change from Baseline indicates improvement.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.8","spread":null},{"groupId":"OG001","value":"9.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Substudy 3: Percentage Of Participants With Endoscopic Improvement at Week 52","description":"Endoscopic improvement is defined as an endoscopic subscore of 0 or 1. Endoscopies were assessed by a blinded central reader and scored according to the following scale: 0 = Normal or inactive disease; 1 = Mild disease (erythema, decreased vascular pattern); 2 = Moderate disease (marked erythema, lack of vascular pattern, any friability, erosions); 3 = Severe disease (spontaneous bleeding, ulceration).","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14.5","spread":null},{"groupId":"OG001","value":"48.7","spread":null},{"groupId":"OG002","value":"61.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Substudy 3: Percentage of Participants With Clinical Remission Per Adapted Mayo Score at Week 52 Among Those Who Achieved Clinical Remission at the End of the Induction Treatment","description":"The Adapted Mayo Score is a composite score of UC disease activity based on the following 3 subscores:\n\n1. Stool frequency subscore (SFS), scored from 0 (normal number of stools) to 3 (5 or more stools more than normal).\n2. Rectal bleeding subscore (RBS), scored from 0 (no blood seen) to 3 (blood alone passed).\n3. Endoscopic subscore, scored from 0 (normal or inactive disease) to 3 (severe disease, spontaneous bleeding, ulceration).\n\nThe overall Adapted Mayo score ranges from 0 to 9 where higher scores represent more severe disease.\n\nFor Substudy 3, clinical remission is defined as SFS ≤ 1 and not greater than Baseline, RBS of 0, and endoscopic subscore ≤ 1. In addition, evidence of friability during endoscopy in participants with otherwise \"mild\" endoscopic activity conferred an endoscopic subscore of 2.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"22.2","spread":null},{"groupId":"OG001","value":"59.2","spread":null},{"groupId":"OG002","value":"69.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Substudy 3: Percentage of Participants Who Achieved Clinical Remission Per Adapted Mayo Score at Wk 52 and Were Corticosteroid Free for ≥ 90 Days Immediately Preceding Wk 52 Among Those Who Achieved Clinical Remission at the End of the Induction Treatment","description":"The Adapted Mayo Score is a composite score of UC disease activity based on the following 3 subscores:\n\n1. Stool frequency subscore (SFS), scored from 0 (normal number of stools) to 3 (5 or more stools more than normal).\n2. Rectal bleeding subscore (RBS), scored from 0 (no blood seen) to 3 (blood alone passed).\n3. Endoscopic subscore, scored from 0 (normal or inactive disease) to 3 (severe disease, spontaneous bleeding, ulceration).\n\nThe overall Adapted Mayo score ranges from 0 to 9 where higher scores represent more severe disease.\n\nFor Substudy 3, clinical remission is defined as SFS ≤ 1 and not greater than Baseline, RBS of 0, and endoscopic subscore ≤ 1. In addition, evidence of friability during endoscopy in participants with otherwise \"mild\" endoscopic activity conferred an endoscopic subscore of 2.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"22.2","spread":null},{"groupId":"OG001","value":"57.1","spread":null},{"groupId":"OG002","value":"68.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Substudy 3: Percentage of Participants With Endoscopic Improvement at Wk 52 Among Those Who Achieved Endoscopic Improvement at the End of the Induction Treatment","description":"Endoscopic improvement is defined as an endoscopic subscore of 0 or 1. Endoscopies were assessed by a blinded central reader and scored according to the following scale: 0 = Normal or inactive disease; 1 = Mild disease (erythema, decreased vascular pattern); 2 = Moderate disease (marked erythema, lack of vascular pattern, any friability, erosions); 3 = Severe disease (spontaneous bleeding, ulceration).","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"19.2","spread":null},{"groupId":"OG001","value":"61.6","spread":null},{"groupId":"OG002","value":"69.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Substudy 3: Percentage Of Participants With Endoscopic Remission At Week 52","description":"Endoscopic remission is defined as an endoscopic subscore of 0. Endoscopies were assessed by a blinded central reader and scored according to the following scale: 0 = Normal or inactive disease; 1 = Mild disease (erythema, decreased vascular pattern); 2 = Moderate disease (marked erythema, lack of vascular pattern, any friability, erosions); 3 = Severe disease (spontaneous bleeding, ulceration).","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.6","spread":null},{"groupId":"OG001","value":"24.2","spread":null},{"groupId":"OG002","value":"25.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Substudy 3: Percentage Of Participants Who Maintained Clinical Response Per Adapted Mayo Score at Wk 52 Among Those Who Achieved Clinical Response at the End of the Induction Treatment","description":"The Adapted Mayo Score is a composite score of UC disease activity based on the following 3 subscores:\n\n1. Stool frequency subscore (SFS), scored from 0 (normal number of stools) to 3 (5 or more stools more than normal).\n2. Rectal bleeding subscore (RBS), scored from 0 (no blood seen) to 3 (blood alone passed).\n3. Endoscopic subscore, scored from 0 (normal or inactive disease) to 3 (severe disease, spontaneous bleeding, ulceration).\n\nThe overall Adapted Mayo score ranges from 0 to 9 where higher scores represent more severe disease. Clinical response is defined as a decrease from baseline in the Adapted Mayo score ≥ 2 points and ≥ 30% from baseline, and a decrease in RBS ≥ 1 or an absolute RBS ≤ 1).","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"18.8","spread":null},{"groupId":"OG001","value":"63.0","spread":null},{"groupId":"OG002","value":"76.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Substudy 3: Percentage Of Participants Who Achieved Histologic-Endoscopic Mucosal Improvement at Week 52","description":"Histologic-endoscopic mucosal improvement is defined as an endoscopic subscore of 0 or 1 and a Geboes score ≤ 3.1.\n\nThe endoscopic subscore ranges from 0 (normal or inactive disease) to 3 (severe disease with spontaneous bleeding, ulceration).\n\nThe Geboes histologic index includes seven histological features (architectural change, chronic inflammatory infiltrate, lamina propria neutrophils and eosinophils, neutrophils in epithelium, crypt destruction and erosion or ulcers). The Geboes score has 6 grades, each with 3-5 subgrades: Grade 0, structural change only; Grade 1, chronic inflammation; Grade 2, lamina propria neutrophils and eosinophils; Grade 3, neutrophils in epithelium; Grade 4, crypt destruction; and Grade 5, erosions or ulceration.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11.9","spread":null},{"groupId":"OG001","value":"35.0","spread":null},{"groupId":"OG002","value":"49.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Substudy 3: Change From Baseline in Inflammatory Bowel Disease Questionnaire (IBDQ) Total Score at Week 52","description":"The Inflammatory Bowel Disease Questionnaire (IBDQ) is used to assess health-related quality of life (HRQoL) in patients with ulcerative colitis. It consists of 32 questions evaluating bowel and systemic symptoms, as well as emotional and social functions. Each question is answered on a scale from 1 (worst) to 7 (best). The total score ranges from 32 to 224 with higher scores indicating better health-related quality of life. A positive change from Baseline indicates improvement.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"17.9","spread":null},{"groupId":"OG001","value":"49.2","spread":null},{"groupId":"OG002","value":"58.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Substudy 3: Percentage Of Participants With Mucosal Healing at Week 52","description":"Mucosal healing is defined as an endoscopic score of 0 and Geboes score \\< 2.0. The endoscopic subscore ranges from 0 (normal or inactive disease) to 3 (severe disease with spontaneous bleeding, ulceration).\n\nThe Geboes histologic index includes seven histological features (architectural change, chronic inflammatory infiltrate, lamina propria neutrophils and eosinophils, neutrophils in epithelium, crypt destruction and erosion or ulcers). The Geboes score has 6 grades, each with 3-5 subgrades: Grade 0, structural change only; Grade 1, chronic inflammation; Grade 2, lamina propria neutrophils and eosinophils; Grade 3, neutrophils in epithelium; Grade 4, crypt destruction; and Grade 5, erosions or ulceration.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.7","spread":null},{"groupId":"OG001","value":"17.6","spread":null},{"groupId":"OG002","value":"19.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Substudy 3: Percentage Of Participants Who Reported No Bowel Urgency at Week 52","description":"Bowel urgency was assessed by participants in a subject diary completed once a day.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"17.4","spread":null},{"groupId":"OG001","value":"56.1","spread":null},{"groupId":"OG002","value":"63.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Substudy 3: Percentage Of Participants Who Reported No Abdominal Pain at Week 52","description":"Abdominal pain was assessed by participants in a subject diary completed once a day.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"20.8","spread":null},{"groupId":"OG001","value":"45.9","spread":null},{"groupId":"OG002","value":"55.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Substudy 3: Change From Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Score at Week 52","description":"The FACIT fatigue questionnaire was developed to assess fatigue associated with anemia. It consists of 13 fatigue-related questions. Each question is answered on a 5-point Likert scale: 0 (not at all); 1 (a little bit); 2 (somewhat); 3 (quite a bit); and 4 (very much). The total score ranges from 0 to 52, where higher scores represent less fatigue, and a positive change from Baseline indicates improvement.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.7","spread":null},{"groupId":"OG001","value":"8.7","spread":null},{"groupId":"OG002","value":"9.5","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":5,"n":46},"commonTop":["COLITIS ULCERATIVE","NASOPHARYNGITIS","HEADACHE","BLOOD CREATINE PHOSPHOKINASE INCREASED","ARTHRALGIA"]}}}